研究园简易版
·
经典书籍
·
期刊文章
·
有原文
·
完整版(可多选筛选、搜索)
·
首页
搜索
2017 年 · Clinical Trials(临床试验)
111 篇,新的在前。点标题看作者和摘要。
回到 2017 年
Bayesian Phase II optimization for time-to-event data based on historical information
· SMMR · 2017-12-28 · 在第 1 页
Sample size determination for jointly testing a cause‐specific hazard and the all‐cause hazard in the presence of competing risks
· SiM · 2017-12-27 · 在第 1 页
A Bayesian framework for performance assessment and comparison of imaging biomarker quantification methods
· SMMR · 2017-12-22 · 在第 1 页
Using threshold regression to analyze survival data from complex surveys: With application to mortality linked NHANES III Phase II genetic data
· SiM · 2017-12-18 · 在第 1 页
Optimized adaptive enrichment designs
· SMMR · 2017-12-18 · 在第 1 页
On causal estimation using $U$-statistics
· Biometrika · 2017-12-14 · 在第 2 页
Test procedure and sample size determination for a proportion study using a double-sampling scheme with two fallible classifiers
· SMMR · 2017-12-12 · 在第 2 页
An oncology clinical trial design with randomization adaptive to both short- and long-term responses
· SMMR · 2017-12-12 · 在第 2 页
Dynamic Borrowing Through Empirical Power Priors that Control Type I Error
· Biometrics · 2017-12-11 · 在第 2 页
Multiplicity considerations in subgroup analysis
· SiM · 2017-12-10 · 在第 2 页
Sharpening randomization-based causal inference for 2 2 factorial designs with binary outcomes
· SMMR · 2017-12-05 · 在第 2 页
Relative efficiency of precision medicine designs for clinical trials with predictive biomarkers
· SiM · 2017-12-04 · 在第 2 页
A weighted combined effect measure for the analysis of a composite time‐to‐first‐event endpoint with components of different clinical relevance
· SiM · 2017-12-04 · 在第 2 页
Sample size requirements for learning to classify with high-dimensional biomarker panels
· SMMR · 2017-11-28 · 在第 3 页
Futility for subgroup analyses in the adaptive signature design
· SMMR · 2017-11-27 · 在第 3 页
Efficient baseline utilization for incomplete block crossover clinical trials
· SMMR · 2017-11-27 · 在第 3 页
Assessing the similarity of dose response and target doses in two non‐overlapping subgroups
· SiM · 2017-11-27 · 在第 3 页
Internal pilot design for balanced repeated measures
· SiM · 2017-11-21 · 在第 3 页
Robustness of crossover trials against subject drop-out – Examples of perpetually connected designs
· SMMR · 2017-11-16 · 在第 4 页
Power and sample size for multivariate logistic modeling of unmatched case-control studies
· SMMR · 2017-11-16 · 在第 4 页
Exact statistical calculation of the uncertainty term in the decision limits of the GH-2000 score for growth hormone misuse (doping) detection
· SMMR · 2017-11-16 · 在第 4 页
Estimating individual benefits of medical or behavioral treatments in severely ill patients
· SMMR · 2017-11-08 · 在第 4 页
Multiply adjusted comparisons: A meta-analysis method to compare single-arm clinical-trial data to literature results regarding a competitor
· SMMR · 2017-10-13 · 在第 6 页
Impact of non-uniform correlation structure on sample size and power in multiple-period cluster randomised trials
· SMMR · 2017-10-13 · 在第 6 页
Optimal designs for active controlled dose-finding trials with efficacy-toxicity outcomes
· Biometrika · 2017-10-09 · 在第 6 页
Spectrum estimation from samples
· AoS · 2017-10-01 · 在第 6 页
Optimal designs for dose response curves with common parameters
· AoS · 2017-10-01 · 在第 7 页
Sample size considerations for paired experimental design with incomplete observations of continuous outcomes
· SMMR · 2017-09-28 · 在第 7 页
Bayesian noninferiority test for 2 binomial probabilities as the extension of Fisher exact test
· SiM · 2017-09-27 · 在第 7 页
Treatment evaluation for a data‐driven subgroup in adaptive enrichment designs of clinical trials
· SiM · 2017-09-26 · 在第 7 页
Type I error probability spending for post–market drug and vaccine safety surveillance with binomial data
· SiM · 2017-09-25 · 在第 7 页
Adaptive Designs for the One-sample Log-rank Test
· Biometrics · 2017-09-22 · 在第 8 页
Sample Size Determination for Multilevel Hierarchical Designs Using Generalized Linear Mixed Models
· Biometrics · 2017-09-12 · 在第 8 页
Sample size considerations for n -of-1 trials
· SMMR · 2017-09-07 · 在第 8 页
Understanding MCP‐MOD dose finding as a method based on linear regression
· SiM · 2017-09-06 · 在第 8 页
A model‐based conditional power assessment for decision making in randomized controlled trial studies
· SiM · 2017-09-04 · 在第 8 页
Two‐stage designs versus European scaled average designs in bioequivalence studies for highly variable drugs: Which to choose?
· SiM · 2017-08-29 · 在第 9 页
Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements
· SiM · 2017-08-28 · 在第 9 页
A synthetic estimator for the efficacy of clinical trials with all‐or‐nothing compliance
· SiM · 2017-08-18 · 在第 9 页
A method to compare the performance of two molecular diagnostic tools in the absence of a gold standard
· SMMR · 2017-08-17 · 在第 9 页
A clinical trial design using the concept of proportional time using the generalized gamma ratio distribution
· SiM · 2017-08-16 · 在第 9 页
Inference for multimarker adaptive enrichment trials
· SiM · 2017-08-10 · 在第 9 页
Subgroup detection and sample size calculation with proportional hazards regression for survival data
· SiM · 2017-08-08 · 在第 9 页
Stepped wedge designs: insights from a design of experiments perspective
· SiM · 2017-08-08 · 在第 9 页
STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials
· SiM · 2017-08-07 · 在第 10 页
A pattern‐mixture model approach for handling missing continuous outcome data in longitudinal cluster randomized trials
· SiM · 2017-08-07 · 在第 10 页
Bayesian Phase I/II Biomarker-Based Dose Finding for Precision Medicine With Molecularly Targeted Agents
· JASA · 2017-07-13 · 在第 12 页
Covariate-adjusted Response-adaptive Randomization for Multi-arm Clinical Trials Using a Modified Forward Looking Gittins Index Rule
· Biometrics · 2017-07-06 · 在第 12 页
Empirical likelihood inference in randomized clinical trials
· SMMR · 2017-07-05 · 在第 12 页
Composite and multicomponent end points in clinical trials
· SiM · 2017-07-04 · 在第 12 页
Testing for qualitative heterogeneity: An application to composite endpoints in survival analysis
· SMMR · 2017-07-03 · 在第 12 页
Some remaining challenges regarding multiple endpoints in clinical trials
· SiM · 2017-06-30 · 在第 12 页
Modelling and sample size reestimation for longitudinal count data with incomplete follow up
· SMMR · 2017-06-21 · 在第 13 页
Comparing cluster-level dynamic treatment regimens using sequential, multiple assignment, randomized trials: Regression estimation and sample size considerations
· SMMR · 2017-06-19 · 在第 13 页
How serious is bias in effect estimation in randomised trials with survival data given risk heterogeneity and informative censoring?
· SiM · 2017-06-15 · 在第 13 页
Using Poisson–gamma model to evaluate the duration of recruitment process when historical trials are available
· SiM · 2017-06-12 · 在第 14 页
Sample size planning of two-arm superiority and noninferiority survival studies with discrete follow-up
· SiM · 2017-06-12 · 在第 14 页
Blinded sample size re‐estimation in three‐arm trials with ‘gold standard’ design
· SiM · 2017-06-12 · 在第 14 页
BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints
· SiM · 2017-06-07 · 在第 14 页
A framework for prospectively defining progression rules for internal pilot studies monitoring recruitment
· SMMR · 2017-06-07 · 在第 14 页
Information‐adaptive clinical trials with selective recruitment and binary outcomes
· SiM · 2017-06-05 · 在第 14 页
Multidimensional latent trait linear mixed model: an application in clinical studies with multivariate longitudinal outcomes
· SiM · 2017-06-01 · 在第 15 页
Missing binary outcomes under covariate‐dependent missingness in cluster randomised trials
· SiM · 2017-05-29 · 在第 15 页
Bias and inference from misspecified mixed‐effect models in stepped wedge trial analysis
· SiM · 2017-05-28 · 在第 15 页
Extended two-stage adaptive designs with three target responses for phase II clinical trials
· SMMR · 2017-05-23 · 在第 15 页
Multi-subgroup Gene Screening Using Semi-parametric Hierarchical Mixture Models and the Optimal Discovery Procedure: Application to a Randomized Clinical Trial in Multiple Myeloma
· Biometrics · 2017-05-12 · 在第 16 页
Validation of surrogate endpoints in cancer clinical trials via principal stratification with an application to a prostate cancer trial
· SiM · 2017-05-08 · 在第 16 页
Hierarchical models for sharing information across populations in phase I dose-escalation studies
· SMMR · 2017-05-08 · 在第 16 页
Economic evaluation of factorial randomised controlled trials: challenges, methods and recommendations
· SiM · 2017-05-03 · 在第 17 页
Accurate p‐values for adaptive designs with binary endpoints
· SiM · 2017-05-03 · 在第 17 页
The use of permutation tests for the analysis of parallel and stepped‐wedge cluster‐randomized trials
· SiM · 2017-05-02 · 在第 17 页
Patient subgroup identification for clinical drug development
· SiM · 2017-04-30 · 在第 17 页
Simulation-based adjustment after exploratory biomarker subgroup selection in phase II
· SiM · 2017-04-24 · 在第 18 页
Surrogate marker analysis in cancer clinical trials through time-to-event mediation techniques
· SMMR · 2017-04-20 · 在第 18 页
Change-Plane Analysis for Subgroup Detection and Sample Size Calculation
· JASA · 2017-04-13 · 在第 18 页
A design for phase I trials in completely or partially ordered groups
· SiM · 2017-04-06 · 在第 19 页
Tests for high-dimensional data based on means, spatial signs and spatial ranks
· AoS · 2017-04-01 · 在第 19 页
Design and Monitoring of Multi-Arm Multi-Stage Clinical Trials
· Biometrics · 2017-03-27 · 在第 20 页
Estimation of treatment effect in two-stage confirmatory oncology trials of personalized medicines
· SiM · 2017-03-17 · 在第 20 页
Toxicity‐dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials
· SiM · 2017-03-15 · 在第 20 页
Clinical trials with nested subgroups: Analysis, sample size determination and internal pilot studies
· SMMR · 2017-03-14 · 在第 21 页
Semiparametric Dose Finding Methods
· JRSSB · 2017-03-09 · 在第 21 页
Analysis of small sample size studies using nonparametric bootstrap test with pooled resampling method
· SiM · 2017-03-09 · 在第 21 页
Bayesian Population Finding with Biomarkers in a Randomized Clinical Trial
· Biometrics · 2017-03-03 · 在第 21 页
Adaptive Designs for Non-inferiority Trials with Multiple Experimental Treatments
· SMMR · 2017-03-01 · 在第 21 页
Quantitative imaging biomarkers: Effect of sample size and bias on confidence interval coverage
· SMMR · 2017-02-27 · 在第 21 页
Bias away from the null due to miscounted outcomes? A case study on the TORCH trial
· SMMR · 2017-02-23 · 在第 22 页
Closed-form REML estimators and sample size determination for mixed effects models for repeated measures under monotone missingness
· SiM · 2017-02-22 · 在第 22 页
Individual treatment effect prediction for amyotrophic lateral sclerosis patients
· SMMR · 2017-02-21 · 在第 22 页
Including historical data in the analysis of clinical trials: Is it worth the effort?
· SMMR · 2017-02-21 · 在第 22 页
A generalized partially linear mean-covariance regression model for longitudinal proportional data, with applications to the analysis of quality of life data from cancer clinical trials
· SiM · 2017-02-19 · 在第 22 页
Comparison of conditional bias-adjusted estimators for interim analysis in clinical trials with survival data
· SiM · 2017-02-17 · 在第 22 页
Bayesian Response-Adaptive Designs for Basket Trials
· Biometrics · 2017-02-17 · 在第 22 页
Quantifying the bias in the estimated treatment effect in randomized trials having interim analyses and a rule for early stopping for futility
· SiM · 2017-02-09 · 在第 22 页
Power and sample size calculation for paired recurrent events data based on robust nonparametric tests
· SiM · 2017-02-09 · 在第 23 页
Maximin Optimal Designs for Cluster Randomized Trials
· Biometrics · 2017-02-09 · 在第 23 页
Designing fecal microbiota transplant trials that account for differences in donor stool efficacy
· SMMR · 2017-02-09 · 在第 23 页
Identification of treatment responders based on multiple longitudinal outcomes with applications to multiple sclerosis patients
· SiM · 2017-02-01 · 在第 23 页
Bayesian joint analysis of heterogeneous- and skewed-longitudinal data and a binary outcome, with application to AIDS clinical studies
· SMMR · 2017-01-30 · 在第 23 页
Statistical methods for unidirectional switch designs: Past, present, and future
· SMMR · 2017-01-26 · 在第 24 页
Generalizability analysis for clinical trials: a simulation study
· SiM · 2017-01-26 · 在第 24 页
Two‐sample binary phase 2 trials with low type I error and low sample size
· SiM · 2017-01-24 · 在第 24 页
Sizing clinical trials when comparing bivariate time‐to‐event outcomes
· SiM · 2017-01-24 · 在第 24 页
Conditional Estimation in Two-Stage Adaptive Designs
· Biometrics · 2017-01-18 · 在第 24 页
An efficient basket trial design
· SiM · 2017-01-18 · 在第 24 页
An efficient test based on the inferential model for the non-inferiority of odds ratio in matched-pairs design
· SMMR · 2017-01-17 · 在第 25 页
Using Ranked Set Sampling With Cluster Randomized Designs for Improved Inference on Treatment Effects
· JASA · 2017-01-12 · 在第 25 页
Sample size calculations for randomised trials including both independent and paired data
· SiM · 2017-01-10 · 在第 25 页
An approach for sample size determination of average bioequivalence based on interval estimation
· SiM · 2017-01-09 · 在第 25 页
Personalized Dose Finding Using Outcome Weighted Learning
· JASA · 2017-01-04 · 在第 26 页
Accounting for competing risks in randomized controlled trials: a review and recommendations for improvement
· SiM · 2017 · 在第 31 页